Dr. Dhruv Khullar

speaker

279 appearances 1 recordings 1 series first heard Jun 2026 last heard 23 Jun

Dr. Dhruv Khullar’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jun 2026 with 1.

Appearances

newest first · ▶ plays the moment

On the Mind with Dr. Daniel Knoepflmacher · On AI and Mental Health: It's Already Here. Are We Ready? · 23 Jun 2026 podcast

What we can do and what we hope to do, I think, is to try to shape how the technology is used and try to make the most of the upsides and mitigate some of the downsides that are clearly also very present.

And so I've been thinking about a couple things.

One is that just because the technology can do something doesn't mean that it necessarily will do that thing.

And so

Part of what we need to be thinking about in healthcare is understanding how do we integrate these technologies in a way that enter the clinical workflow that really help both doctors, nurses, and patients.

And so part of making use of a powerful technology is integrating in the workflow in a way that is positive.

I think the other thing that is really important to note is that technologies exist in a culture.

cultural, social, and economic milieu.

And just because let's take the example of AI scribes or other types of AI documentation, let's say that that makes doctors twice as efficient or it takes a lot off their plates.

One potential way that that could go is that doctors now have a lot more time to talk to their patients, to look them in the eye, to make those connections that many of us went into medicine for.

Another way that it could go is that the expectations are to see twice or more as many patients in the same unit of time.

And that has little to do with the technology itself and more about the decisions that we make about the use of the technology.

And the third thing I'll say is that there are so many claims being made about AI and what it can do.

And there's still relatively little evidence, certainly in the real world, about the application of these technologies.

I don't think that they should be necessarily regulated or held to a standard that we might hold a new chemotherapeutic agent to.

But I do think that there needs to be real efforts to understand the downstream implications.

of integrating some of these technologies into clinical practice.

And right now a lot of the discussion is speculative and it is based on the claims that companies and others are making.

And we need to have a really robust infrastructure of researching what the actual impact is for patients.

Sure.

Showing 41–60 of 279 · page 3 of 14